Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Berger

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|October 14, 2022
Receptor for Advanced Glycation End-Products Promotes Activation of Alveolar Macrophages through the NLRP3 Inflammasome/TXNIP Axis in Acute Lung InjuryWoodys Lenga Ma Bonda, Marianne Fournet, Ruoyang Zhai, et al.
Oncotarget|July 14, 2020
Influence of major <i>BCR-ABL1</i> transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinibAlexis Genthon, Franck Emmanuel Nicolini, Françoise Huguet, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2015
STAT3 Serine 727 Phosphorylation: A Relevant Target to Radiosensitize Human GlioblastomaZangbéwendé Guy Ouédraogo, Mélanie Müller-Barthélémy, Jean-Louis Kemeny, et al.
Pharmacoepidemiology and Drug Safety|September 14, 2020
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiativeLucinda S Orsini, Brigitta Monz, C Daniel Mullins, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 17, 2020
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency InitiativeLucinda S Orsini, Marc Berger, William Crown, et al.
Joint Bone Spine|December 31, 2016
Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjectsChristine Serratrice, Nesma Bensalah, Guillaume Penaranda, et al.
Ejhaem|July 18, 2022
Mast cell density and its clinical relevance in Waldenström's macroglobulinemiaRichard Lemal, Stéphanie Poulain, Albane Ledoux-Pilon, et al.
Cancer|May 4, 2018
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study GroupDelphine Rea, Shanti Ame, Marc Berger, et al.
Leukemia Research|May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemiaMarie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|October 14, 2022
Receptor for Advanced Glycation End-Products Promotes Activation of Alveolar Macrophages through the NLRP3 Inflammasome/TXNIP Axis in Acute Lung InjuryWoodys Lenga Ma Bonda, Marianne Fournet, Ruoyang Zhai, et al.
Oncotarget|July 14, 2020
Influence of major <i>BCR-ABL1</i> transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinibAlexis Genthon, Franck Emmanuel Nicolini, Françoise Huguet, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2015
STAT3 Serine 727 Phosphorylation: A Relevant Target to Radiosensitize Human GlioblastomaZangbéwendé Guy Ouédraogo, Mélanie Müller-Barthélémy, Jean-Louis Kemeny, et al.
Pharmacoepidemiology and Drug Safety|September 14, 2020
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiativeLucinda S Orsini, Brigitta Monz, C Daniel Mullins, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 17, 2020
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency InitiativeLucinda S Orsini, Marc Berger, William Crown, et al.
Joint Bone Spine|December 31, 2016
Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjectsChristine Serratrice, Nesma Bensalah, Guillaume Penaranda, et al.
Ejhaem|July 18, 2022
Mast cell density and its clinical relevance in Waldenström's macroglobulinemiaRichard Lemal, Stéphanie Poulain, Albane Ledoux-Pilon, et al.
Cancer|May 4, 2018
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study GroupDelphine Rea, Shanti Ame, Marc Berger, et al.
Leukemia Research|May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemiaMarie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Pageof 6